Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J M Lewis

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Scientific Reports|January 1, 2020
Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortiumJanuary Weiner, David J M Lewis, Jeroen Maertzdorf, et al.
NPJ Systems Biology and Applications|July 21, 2017
MUFINS: multi-formalism interaction network simulatorHuihai Wu, Axel von Kamp, Vytautas Leoncikas, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Infection and Immunity|June 18, 2002
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteersZoë Hindle, Steven N Chatfield, Jo Phillimore, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Microbe|January 13, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsNavin Venkatraman, Alfred B Tiono, Georgina Bowyer, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Scientific Reports|January 1, 2020
Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortiumJanuary Weiner, David J M Lewis, Jeroen Maertzdorf, et al.
NPJ Systems Biology and Applications|July 21, 2017
MUFINS: multi-formalism interaction network simulatorHuihai Wu, Axel von Kamp, Vytautas Leoncikas, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Infection and Immunity|June 18, 2002
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteersZoë Hindle, Steven N Chatfield, Jo Phillimore, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Microbe|January 13, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsNavin Venkatraman, Alfred B Tiono, Georgina Bowyer, et al.
Pageof 5